Moderna, Inc. (MRNA) Stock Price, News, Analysis

Technical Score (1D)

100

BULLISH

News Sentiment

BULLISH

On Oct 13, Moderna, Inc. announced that it would hold a live earnings call and webcast on Nov 6, 2026 to report its third‑quarter 2026 financial results and provide a corporate update. The call would be available on the company’s Investors website and archived for one year. The announcement was described as a routine disclosure of an upcoming earnings release and did not indicate any material change in guidance or performance.

MRNA|Analyst Targets

LOW TARGET

$45 -79.0%

3 analysts

MEAN TARGET

$123 -42.7%

20 analysts

HIGH TARGET

$200 -6.5%

8 analysts

PRICE RANGE

$45.00 - $200.00

SB / B / H / S / SS

4/7/17/2/1

DAILYIQ EST.

$123.67 (-42.2%)

MRNA|Company Info

Sector

Healthcare

Industry

Biotechnology

Exchange

NMS

Country

United States

Website

modernatx.com

Symbol

MRNA

Description

Moderna, Inc. is a biotechnology firm specializing in messenger RNA (mRNA) medicines, with a global presence spanning the United States, Europe, and other international markets. The company's core business centers on developing and commercializing vaccines and therapeutics across various therapeutic areas. Moderna's pipeline includes respiratory vaccines targeting COVID-19, RSV, and influenza, along with programs addressing latent viruses, enteric viruses, bacterial diseases, and public health threats. Beyond vaccines, the company is also developing treatments for oncology and rare diseases. Strategic partnerships with companies like AstraZeneca, Merck, and Vertex Pharmaceuticals, among others, support Moderna's research and development efforts. Established in 2010 and headquartered in Cambridge, Massachusetts, Moderna is focused on advancing mRNA technology to address significant unmet medical needs.

MRNA|Insider Trading

Bought (1Y)

0 shares

Sold (1Y)

831,687 shares

$59.1M

Mock James MChief Financial Officer

Option Exercise1,454 shares2026-10-05

Mock James MChief Financial Officer

Tax Withholding704 shares2026-10-05

Mock James MChief Financial Officer

Option Exercise1,454 shares2026-10-05

Hoge StephenPresident

Option Exercise76,452 shares2026-09-15

Hoge StephenPresident

Sell40,281 shares2026-09-15

MRNA|Fundamentals

Very bearish

Overall: Bearish

✕Revenue declining year over year

✕Negative net margin

✕Negative operating cash flow

Net Margin

-145.2%

Revenue CAGR

37.8%

Current Ratio

3.29x

Debt / Equity

0.07x

Return on Equity

-32.6%

MRNA|Earnings Snapshot

Earnings Summary

Moderna, Inc. is a biotechnology firm specializing in messenger RNA medicines, with a global presence and a pipeline that includes vaccines for COVID‑19, RSV, influenza, and oncology therapeutics. In the most recent two quarters, Moderna’s EPS improved from a loss of $2.52 in Q1 2025 to a loss of $0.51 in Q3 2025, while revenue rose from $108 million to $1.016 billion, marking a 9.4% YoY increase in earnings and a 9.4% YoY jump in sales; the company has consistently missed EPS estimates in all quarters, yet revenue has outpaced forecasts in Q3 2025 by 2.3%. Historically, Moderna has shown a pattern of narrowing losses, with EPS moving from a $2.91 loss in Q4 2024 to a $1.97 loss in Q2 2026, and revenue growth of 14.8% in Q4 2025 and 18.5% in Q1 2026, indicating a gradual improvement in operating performance. Recent news indicates a routine earnings call announcement for Q3 2026 and a return to the Nasdaq‑100 index, alongside a leadership change to accelerate personalized cancer vaccine scaling; these developments suggest a strategic focus on expanding oncology capabilities. Forward‑looking watch points for investors include observing the Q3 2026 earnings release for any further narrowing of losses, evaluating guidance adjustments for oncology pipeline milestones, and monitoring the impact of manufacturing capacity expansions on future revenue streams.

Read full report

EPS

EstBeatMiss

Qtr	Est	Actual	+/−
Q3'26	$-1.30	-	-
Q2'26	$-2.12	$-1.97	+7.3%
Q1'26	$-1.96	$-1.18	+39.6%
Q4'25	$-2.18	$-2.11	+3.4%
Q3'25	$-2.18	$-0.51	+76.6%
Q2'25	$-2.97	$-2.13	+28.3%

Revenue

EstBeatMiss

Qtr	Est	Actual	+/−
Q3'26	$892M	-	-
Q2'26	$105M	$145M	+38.0%
Q1'26	$92M	$389M	+321.1%
Q4'25	$254M	$678M	+167.1%
Q3'25	-	$1.0B	-
Q2'25	-	$142M	-

Full Earnings BreakdownEstimates, actuals, guidance, and historical context

→

MRNA|Monthly Returns

Market Data

MRNA Stock Snapshot

BULLISH100/100

$215.00−$0.82 (0.4%)

Market cap: 85.68B
Day range: $213.00 – $217.95
News sentiment: 55/100 · Neutral
Analyst target: $122.67 (-42.9%)
Consensus: Hold · 31 analysts

52-week range+865.4% off low · -5.5% from high

$22.27$227.46

Price $215.00 DailyIQ Est. $123.67

Moderna, Inc. screens well technically, with price sitting near its 52-week high. Sector peers are worth watching - large caps in Healthcare tend to move together on rotation.

Sector Rotation

Is money rotating into or out of MRNA's sector?

Moderna, Inc. sits in the Health Care sector, currently ranked 4th of 12 GICS sectors by relative-strength rotation score (improving). Within its narrower Biotechnology industry group, MRNA ranks 11th of 15 tracked industries, lagging.

Sector rank: #4 of 12
Sector state: Improving
Sector rotation score: 82
Industry rank: #11 of 15

Options Market

What is the options market pricing for MRNA?

CallsPuts

For Moderna, Inc.'s nearest expiry (2026-10-16, 2 days out), open interest is call-heavy, a bullish tilt (put/call ratio of 0.54), with at-the-money implied volatility around 12.5%. The options market is pricing roughly a ±0.9% move by that expiry — a range of about $222.87–$227.03.

Put/call ratio (2026-10-16): 0.54
ATM implied volatility: 12.5%
Total open interest: 90,906
Expected move by 2026-10-16: ±0.9% ($222.87–$227.03)

Analyst Rating Changes

Are analysts turning bullish or bearish on MRNA?

Morgan Stanley most recently reiterated its rating on Moderna, Inc. to Equal-Weight on Oct 7, 2026 with a price target of $95 (from $89). Over the last 90 days, coverage has run 3 upgrades against 2 downgrades, a net bullish lean.

Latest action: Morgan Stanley — Equal-Weight
90-day upgrades: 3
90-day downgrades: 2
Net rating momentum: +1

Date	Firm	Action	Rating	Price target
Oct 7, 2026	Morgan Stanley	Maintained	Equal-Weight	$89 → $95
Sep 30, 2026	Citigroup	Downgrade	Neutral → Sell	$60 → $80
Sep 3, 2026	Rothschild & Co	Downgrade	Neutral → Sell	$40 → $81
Aug 28, 2026	Argus Research	Upgrade	Hold → Buy	$180
Aug 25, 2026	Wolfe Research	Upgrade	Underperform → Peer Perform	-
Aug 24, 2026	Barclays	Maintained	Equal-Weight	$48 → $125
Aug 21, 2026	JP Morgan	Maintained	Underweight	$40 → $77
Aug 20, 2026	Goldman Sachs	Maintained	Neutral	$67 → $120
Aug 20, 2026	UBS	Maintained	Neutral	$50 → $150
Aug 20, 2026	Morgan Stanley	Maintained	Equal-Weight	$39 → $89
Aug 19, 2026	William Blair	Upgrade	Market Perform → Outperform	-
Aug 3, 2026	Citigroup	Maintained	Neutral	$41 → $60

Peers & ETF holders

MRNA peers & ETF holders

BiotechnologyMarket cap · today

Top ETF holdersWeight

News Sentiment Analysis

Sentiment gathered from recent headlines

55/100

Strong NegativeNeutralStrong Positive

MODERATELY BULLISH

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles

What did this article say?

Moderna, Inc. (NASDAQ:MRNA) announced on October 13, 2026 that it would host a live conference call and webcast on November 6, 2026 to report its third‑quarter 2026 financial results and provide a corporate update. The event will be available on the company’s Investors website and archived for one year. The announcement is a routine disclosure of an upcoming earnings release and does not indicate any material change in guidance or performance.

What did this article say?

Moderna’s market capitalization has risen to nearly $90 billion, outpacing BioNTech by more than threefold. The rally is largely attributed to a late‑stage Phase 3 trial of its personalized mRNA cancer vaccine, intismeran autogene, combined with Merck’s Keytruda in melanoma patients. The trial’s positive results have repositioned Moderna from a post‑COVID laggard to a leading mRNA cancer platform, generating significant investor enthusiasm and a 660% year‑to‑date share price increase.

What did this article say?

Moderna was reinstated to the Nasdaq‑100 index and announced the return of former manufacturing chief Juan Andres as COO to scale its personalized cancer vaccine, intismeran autogene, after positive Phase 3 melanoma results. The dual developments signal a strategic pivot toward oncology and broader portfolio diversification beyond COVID‑19. The market reacted strongly, lifting the stock by 18.4% on the day of the announcement.

What did this article say?

Moderna’s share price rebounded sharply after a 7‑year run, prompting analysts to question whether the current $225 level is justified by the company’s revenue trajectory. The focus shifted to the alignment between the firm’s sales base and its market valuation. Recent developments in mRNA manufacturing capacity and oncology trial progress were highlighted as potential long‑term revenue drivers. However, the steep price increase raised concerns that the market may be overestimating future earnings. The article underscored the need to reassess the valuation in light of current sales performance.

What did this article say?

Moderna’s valuation model was updated, raising the fair value estimate from $119.56 to $122.67 per share. The increase reflects optimism around the company’s intismeran cancer vaccine program, particularly Phase 3 melanoma data. Some analysts remain cautious, citing uncertainties in oncology revenue assumptions, but the overall sentiment is that the higher price target is supported by recent clinical progress. The adjustment signals a modest lift in investor expectations for the company’s future earnings.

What did this article say?

Moderna’s shares jumped 61% above the average Wall Street price target after a decade of muted performance. The rally was driven by renewed investor enthusiasm for the company’s personalized cancer vaccine program, which has shown promising early data. The stock’s recent surge reflects optimism about future product launches, but no new regulatory approvals or earnings guidance were announced to substantiate the upside. The market’s reaction underscores a belief that the company’s pipeline could revive growth, though the move remains speculative without concrete milestones.

What did this article say?

On October 9, Moderna’s stock climbed to a fresh 52‑week high after the company reentered the Nasdaq‑100 index, replacing Warner Bros. Discovery. The price increase was amplified by a New York Times article outlining a public‑private partnership aimed at speeding cancer vaccine development, echoing the success of the COVID‑19 vaccine collaboration. Bank of America also raised its price target to $200 from $170, underscoring the positive market sentiment.

What did this article say?

Moderna’s stock climbed 9% after a New York Times story revealed that the National Institutes of Health is joining a public‑private partnership to speed up cancer vaccine development. The partnership signals increased funding and regulatory support for Moderna’s oncology pipeline. The share price movement reflected investor optimism about potential future product launches and expanded market opportunities.

What did this article say?

Moderna’s addition to the NASDAQ 100 triggered a 5% jump in its shares as index funds began mechanical purchases. The move positioned the company within a major growth benchmark, potentially increasing long‑term visibility and liquidity. While the rally may be partly driven by index mechanics, the inclusion signals broader market confidence in Moderna’s pipeline and valuation. The impact is material, reflecting a positive catalyst for the stock.

Technical Analysis

Real-time indicators across multiple timeframes

100

BULLISH

Momentum rank against about 1,000 stocks and ETFs for this timeframe.

Unlock full technicals

Create a free account to access more indicators and deeper timeframe data.

Institutional & Hedge Fund Ownership

25 tracked managers · $13.50B combined position · 17 adding, 8 trimming, 0 unchanged (latest 13F filings)

Manager	Trend	Shares Held	% of Co.	Position Value	Filed
FMR LLC (Fidelity)	▲ Buy	51,859,891	13.03%	$3.63B	2026-08-13
BlackRock, Inc.	▲ Buy	30,599,409	7.69%	$2.14B	2026-08-07
Capital World Investors	▲ Buy	22,276,996	5.60%	$1.56B	2026-08-12
Baillie Gifford & Co	▼ Sell	18,206,778	4.58%	$1.28B	2026-08-06
Vanguard Group Inc	▲ Buy	41,584,782	10.45%	$1.23B	2026-01-29
Geode Capital Management, LLC	▲ Buy	9,710,335	2.44%	$678.82M	2026-08-12
Morgan Stanley	▲ Buy	9,538,094	2.40%	$667.95M	2026-08-13
Two Sigma Investments, LP	▼ Sell	7,193,530	1.81%	$503.76M	2026-08-14
Invesco Ltd.	▲ Buy	5,780,299	1.45%	$404.79M	2026-08-14
Goldman Sachs Group Inc	▼ Sell	4,671,950	1.17%	$327.18M	2026-08-14
Norges Bank	▲ Buy	3,026,074	0.76%	$211.92M	2026-08-12
Northern Trust Corp	▲ Buy	2,985,329	0.75%	$209.06M	2026-08-13
Wellington Management Group LLP	▲ Buy	2,461,574	0.62%	$172.38M	2026-08-14
Citigroup Inc	▲ Buy	2,165,414	0.54%	$151.64M	2026-08-03
Bank of America Corp	▲ Buy	1,409,679	0.35%	$98.72M	2026-08-14
JPMorgan Chase & Co	▼ Sell	837,452	0.21%	$59.52M	2026-08-12
AQR Capital Management LLC	▲ Buy	479,141	0.12%	$33.55M	2026-08-14
Millennium Management LLC	▼ Sell	438,615	0.11%	$30.72M	2026-08-14
Susquehanna International Group, LLP	▲ Buy	357,774	0.09%	$25.05M	2026-08-14
Citadel Advisors LLC	▼ Sell	294,496	0.07%	$20.62M	2026-09-02
AllianceBernstein L.P.	▲ Buy	398,005	0.10%	$20.22M	2026-08-14
Brevan Howard Capital Management LP	▲ Buy	181,105	0.05%	$12.68M	2026-08-14
Prudential Financial Inc	▼ Sell	169,201	0.04%	$11.85M	2026-08-12
Adage Capital Partners GP, L.L.C.	▲ Buy	156,716	0.04%	$10.97M	2026-08-14
Wells Fargo & Company	▼ Sell	123,037	0.03%	$8.62M	2026-08-14

Q2 2026 flow:15.53M sh bought ($1.09B)6.88M sh sold ($482.46M)net +8.65M sh (+$605.04M)

Congressional Trading Activity

6 disclosed trades · ~$48.0K est. traded value · 2 buys, 4 sells

Member	Chamber	State	Type	Amount	Traded	Filed
Maria Elvira Salazar	House	FL27	▼ Sell	$1K - $15K	2026-09-24	2026-10-07
Maria Elvira Salazar	House	FL27	▼ Sell	$1K - $15K	2026-08-19	2026-09-09
Maria Elvira Salazar	House	FL27	▲ Buy	$1K - $15K	2026-08-19	2026-09-09
Rob Bresnahan	House	PA08	▼ Sell	$1K - $15K	2025-04-08	2025-05-08
Rob Bresnahan	House	PA08	▲ Buy	$1K - $15K	2025-02-25	2025-03-27
Julie Johnson	House	TX32	▼ Sell	$1K - $15K	2025-01-15	2025-02-12